Icon

TOTECT (nda022025)- (EQ 500MG BASE/VIAL)

DEXRAZOXANE HYDROCHLORIDE CLINIGEN
EQ 500MG BASE/VIAL
No Yes
2020-Mar-13 Expired
2014-Sep-06 2010-Sep-06
None No
Totect is a cytoprotective agent indicated for: • Treatment of extravasation resulting from intravenous anthracycline chemotherapy. • Reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use Totect with doxorubicin initiation
0 0 0
Total Other Developers None
Drugs with Suitability No
EQ 500MG BASE/VIAL ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.